The recent FDA approval of sarilumab for the treatment of refractory polymyalgia rheumatica may have a significant and lasting impact on the use of long-term steroids for that condition.
PHILADELPHIA — Patients with steroid-resistant polymyalgia rheumatica who received sarilumab and tapered glucocorticoids achieved higher remission rates vs. glucocorticoid taper alone, according to data presented at ACR Convergence 2022.